iRadimed (IRMD) Expected to Announce Earnings on Friday

Key Points

• iRadimed is set to release its Q2 2025 earnings on August 1st, with analysts predicting earnings of $0.45 per share and revenue of $20.01 million.
• The company recently announced a quarterly dividend of $0.17 per share, yielding approximately 1.19% on an annualized basis.
• Institutional investors hold a significant stake in iRadimed, owning 92.34% of the company's stock, with recent increases in stakes from firms like Royal Bank of Canada and Jones Financial Companies.

iRadimed (NASDAQ:IRMD - Get Free Report) will likely be releasing its Q2 2025 earnings data before the market opens on Friday, August 1st. Analysts expect iRadimed to post earnings of $0.45 per share and revenue of $20.01 million for the quarter.

iRadimed Trading Up 1.4%

iRadimed stock traded up $0.79 on Monday, reaching $57.11. 30,634 shares of the stock were exchanged, compared to its average volume of 42,695. The stock has a market cap of $726.15 million, a PE ratio of 36.85 and a beta of 0.91. iRadimed has a twelve month low of $42.34 and a twelve month high of $63.29. The firm has a fifty day moving average price of $57.96 and a two-hundred day moving average price of $55.77.

iRadimed Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, May 30th. Shareholders of record on Tuesday, May 20th were given a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a yield of 1.19%. The ex-dividend date of this dividend was Tuesday, May 20th. iRadimed's dividend payout ratio is 43.87%.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada grew its stake in iRadimed by 14.7% during the first quarter. Royal Bank of Canada now owns 25,782 shares of the medical equipment provider's stock worth $1,354,000 after buying an additional 3,307 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of iRadimed by 7.5% during the first quarter. AQR Capital Management LLC now owns 15,829 shares of the medical equipment provider's stock valued at $831,000 after purchasing an additional 1,108 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of iRadimed by 5.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider's stock valued at $252,000 after purchasing an additional 234 shares during the last quarter. Jones Financial Companies Lllp grew its stake in shares of iRadimed by 8,568.5% during the first quarter. Jones Financial Companies Lllp now owns 11,269 shares of the medical equipment provider's stock valued at $591,000 after purchasing an additional 11,139 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in shares of iRadimed by 1.1% during the first quarter. Goldman Sachs Group Inc. now owns 169,387 shares of the medical equipment provider's stock valued at $8,889,000 after purchasing an additional 1,821 shares during the last quarter. Institutional investors and hedge funds own 92.34% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of iRadimed from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, May 6th.

iRadimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.